Scorpion EnvenomationNCT07408947
Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an Emergency Department
An observational study of Scorpion Envenomation, run by University of Guadalajara at 1 site in Mexico.
Trial summary
Scorpion stings are a common medical emergency in Mexico, particularly in the state of Jalisco. While antivenom is the standard treatment for scorpion envenomation, there is variability in how it is used, including differences in dosing strategies. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Scorpion Envenomation
- Type of treatment
- Injection or infusion
- How many people
- 3,145 participants
- Where
- 1 siteMexico
- Study dates
- 7 Aug 2025to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients of all ages who presented with scorpion envenomation to the emergency department of a public hospital in Jalisco, Mexico, between 2021 and 2024. Patients were evaluated and treated as part of routine clinical care, following local clinical practice and national guidelines.
Who may be able to join
- Patients of any age with a clinical diagnosis of scorpion envenomation.
- Patients evaluated and treated in the emergency department of the participating hospital.
- Availability of medical records with sufficient clinical information to assess envenomation severity, time to medical care, and antivenom administration.
Who cannot join
- Patients with incomplete or missing medical records that do not allow determination of clinical severity or antivenom use.
- Patients transferred from another healthcare facility after having already received definitive treatment for scorpion envenomation.
- Patients with documented co-envenomation or alternative diagnoses that could confound clinical severity assessment.
- Patients who declined medical evaluation or left the emergency department before completion of initial assessment and management.
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Centro Universitario de Ciencias de la Salud
Guadalajara, Jalisco, 44340
About this study
Official title: Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an Emergency Department in Jalisco, Mexico
Scorpion stings are a common medical emergency in Mexico, particularly in the state of Jalisco. While antivenom is the standard treatment for scorpion envenomation, there is variability in how it is used, including differences in dosing strategies. In addition, many patients use home remedies before seeking medical care, which may delay treatment and influence the severity of symptoms.
This study is an observational, retrospective analysis of patients treated for scorpion envenomation in the emergency department of a public hospital in Jalisco, Mexico, between 2021 and 2023. Using information from medical records, the study examines the relationship between the use of home remedies, the time to receive medical care, clinical severity at presentation, and the antivenom dosing strategies used, including traditional and reduced-dose approaches.
The goal of this study is to better understand factors associated with clinical severity and antivenom use in real-world emergency care. The results may help inform future clinical decision-making, promote rational use of antivenom, and improve timely access to appropriate medical treatment for patients with scorpion envenomation.
- Conditions
- Scorpion Envenomation
- Keywords
- antivenom, scorpion, home remedy, scorpionism, scorpion envenomation
- Medical subject headings
- Scorpion Stings
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Reduced dose | This group includes patients diagnosed with scorpion envenomation who were managed using a reduced-dose antivenom strategy during routine emergency care. In this approach, antivenom (faboterápico) was administered primarily to patients with systemic manifestations of envenomation. The initial dose generally consisted of a single intravenous vial, with additional vials administered only if clinical symptoms persisted or progressed after reassessment. Patients who did not receive antivenom because they presented without systemic symptoms were also included in this group. This management strategy differs from the Mexican national Clinical Practice Guidelines, which recommend antivenom administration to all patients with scorpion envenomation, regardless of the presence or absence of systemic symptoms. All treatment decisions were made by the treating physicians as part of standard clinical care, without protocol-mandated interventions. | |
| Traditional dose | This group includes patients diagnosed with scorpion envenomation who were managed according to the traditional antivenom dosing strategy recommended by the Mexican national Clinical Practice Guidelines. These guidelines advise administering antivenom (faboterápico) to all patients with scorpion envenomation, independent of whether systemic symptoms are present, with dosing adjusted based on patient age and clinical severity. Under this strategy, patients typically received one or more intravenous vials of antivenom as an initial dose, with additional doses administered at predefined intervals if symptoms persisted, in accordance with guideline-based algorithms. All treatments were provided as part of routine emergency care, and no interventions were assigned for research purposes. This group reflects standard-of-care antivenom use in Mexico during the study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical resolution of symptoms within 3 hours
Proportion of patients with scorpion envenomation who achieved complete clinical resolution of signs and symptoms within three hours after initial medical management in the emergency department.
Measured: From emergency department admission to 3 hours after initial treatment.
Secondary outcomes (3)
Need for additional antivenom doses
Proportion of patients who required one or more additional doses of antivenom after the initial administration due to persistence or progression of clinical symptoms.
Measured: From initial antivenom administration until emergency department discharge (up to 24 hours)
Total number of antivenom vials administered
Total number of antivenom (faboterápico) vials administered per patient during emergency department management.
Measured: From initial antivenom administration until emergency department discharge (up to 24 hours)
Use of supportive medications
Use of additional supportive medications, including benzodiazepines, anticholinergics, opioids, antiemetics, or other agents, administered during emergency department management.
Measured: From initial antivenom administration until emergency department discharge (up to 24 hours)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start7 Aug 2025
- Primary completion1 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Scorpion EnvenomationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 3,145 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Guadalajara
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christian Johana Baños Hernández, University of Guadalajara
- Investigators
- Christian J Baños, PhD, Study director, University of Guadalajara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07408947
- Sponsor's protocol ID
- Epidemiología del alacranismo
- Status last verified
- Feb 2026
- First submitted
- 15 Jan 2026
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an Emergency Department in Jalisco, Mexico
- ClinicalTrials.gov ID
- NCT07408947
- Acronym / sponsor ID
- Epidemiología del alacranismo
- Conditions
- Scorpion Envenomation
- Keywords
- antivenom, scorpion, home remedy, scorpionism, scorpion envenomation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,145 participants (actual)
- Lead sponsor
- University of GuadalajaraUniversity, hospital or other
- Study start
- 7 Aug 2025 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Scorpion stings are a common medical emergency in Mexico, particularly in the state of Jalisco. While antivenom is the standard treatment for scorpion envenomation, there is variability in how it is used, including differences in dosing strategies. In addition, many patients use home remedies before seeking medical care, which may delay treatment and influence the severity of symptoms.
This study is an observational, retrospective analysis of patients treated for scorpion envenomation in the emergency department of a public hospital in Jalisco, Mexico, between 2021 and 2023. Using information from medical records, the study examines the relationship between the use of home remedies, the time to receive medical care, clinical severity at presentation, and the antivenom dosing strategies used, including traditional and reduced-dose approaches.
The goal of this study is to better understand factors associated with clinical severity and antivenom use in real-world emergency care. The results may help inform future clinical decision-making, promote rational use of antivenom, and improve timely access to appropriate medical treatment for patients with scorpion envenomation.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Reduced dose | – | –This group includes patients diagnosed with scorpion envenomation who were managed using a reduced-dose antivenom strategy during routine emergency care. In this approach, antivenom (faboterápico) was administered primarily to patients with systemic manifestations of envenomation. The initial dose generally consisted of a single intravenous vial, with additional vials administered only if clinical symptoms persisted or progressed after reassessment. Patients who did not receive antivenom because they presented without systemic symptoms were also included in this group. This management strategy differs from the Mexican national Clinical Practice Guidelines, which recommend antivenom administration to all patients with scorpion envenomation, regardless of the presence or absence of systemic symptoms. All treatment decisions were made by the treating physicians as part of standard clinical care, without protocol-mandated interventions. |
| Traditional dose | – | –This group includes patients diagnosed with scorpion envenomation who were managed according to the traditional antivenom dosing strategy recommended by the Mexican national Clinical Practice Guidelines. These guidelines advise administering antivenom (faboterápico) to all patients with scorpion envenomation, independent of whether systemic symptoms are present, with dosing adjusted based on patient age and clinical severity. Under this strategy, patients typically received one or more intravenous vials of antivenom as an initial dose, with additional doses administered at predefined intervals if symptoms persisted, in accordance with guideline-based algorithms. All treatments were provided as part of routine emergency care, and no interventions were assigned for research purposes. This group reflects standard-of-care antivenom use in Mexico during the study period. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients of all ages who presented with scorpion envenomation to the emergency department of a public hospital in Jalisco, Mexico, between 2021 and 2024. Patients were evaluated and treated as part of routine clinical care, following local clinical practice and national guidelines.
Key inclusion criteria (3 listed)
- Patients of any age with a clinical diagnosis of scorpion envenomation.
- Patients evaluated and treated in the emergency department of the participating hospital.
- Availability of medical records with sufficient clinical information to assess envenomation severity, time to medical care, and antivenom administration.
Key exclusion criteria (4 listed)
- Patients with incomplete or missing medical records that do not allow determination of clinical severity or antivenom use.
- Patients transferred from another healthcare facility after having already received definitive treatment for scorpion envenomation.
- Patients with documented co-envenomation or alternative diagnoses that could confound clinical severity assessment.
- Patients who declined medical evaluation or left the emergency department before completion of initial assessment and management.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical resolution of symptoms within 3 hours
Time frame: From emergency department admission to 3 hours after initial treatment.
Proportion of patients with scorpion envenomation who achieved complete clinical resolution of signs and symptoms within three hours after initial medical management in the emergency department.
3 secondary outcomes
Need for additional antivenom doses
Time frame: From initial antivenom administration until emergency department discharge (up to 24 hours)
Total number of antivenom vials administered
Time frame: From initial antivenom administration until emergency department discharge (up to 24 hours)
Use of supportive medications
Time frame: From initial antivenom administration until emergency department discharge (up to 24 hours)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian J Baños, PhD study director
University of Guadalajara
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Scorpion Envenomation, run by University of Guadalajara at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical resolution of symptoms within 3 hours (time frame: From emergency department admission to 3 hours after initial treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.